Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Receivables (2017 - 2025)

Tvardi Therapeutics' Receivables history spans 10 years, with the latest figure at $2.2 million for Q1 2025.

  • On a quarterly basis, Receivables rose 0.63% to $2.2 million in Q1 2025 year-over-year; TTM through Mar 2025 was $2.2 million, a 0.63% increase, with the full-year FY2024 number at $4.5 million, up 35.39% from a year prior.
  • Receivables hit $2.2 million in Q1 2025 for Tvardi Therapeutics, down from $4.5 million in the prior quarter.
  • Over the last five years, Receivables for TVRD hit a ceiling of $40.4 million in Q3 2021 and a floor of $305000.0 in Q2 2021.
  • Historically, Receivables has averaged $5.7 million across 5 years, with a median of $2.8 million in 2023.
  • Biggest five-year swings in Receivables: soared 8640.48% in 2021 and later plummeted 89.39% in 2024.
  • Tracing TVRD's Receivables over 5 years: stood at $455000.0 in 2021, then surged by 723.96% to $3.7 million in 2022, then fell by 11.44% to $3.3 million in 2023, then surged by 35.39% to $4.5 million in 2024, then crashed by 50.21% to $2.2 million in 2025.
  • Business Quant data shows Receivables for TVRD at $2.2 million in Q1 2025, $4.5 million in Q4 2024, and $534000.0 in Q3 2024.